Monograph
J07AG01 - Haemophilus Influenzae B, Purified Antigen Conjugated |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the hemophilus influenzae B, purified antigen conjugated vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Haemophilus influenzae type b polysaccaride conjugated to tetanus carrier protein.
Therapeutic characteristics
The hemophilus influenza B vaccine is indicated for the prevention of invasive disease caused by Haemophilus influenzae type b in children from 2 months through 5 years of age. It is administered by intramuscular injections, in infants usually according to a three or four dose schedule.
Metabolism and pharmacokinetics
The hemophilus influenza B vaccine is not metabolized by the cytochrome P450 system.
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | Norwegian medicines agency. Summary of Product Characteristics (SPC). Act-Hib.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Norway
Poland
Luxembourg
Iceland
Finland© NAPOS 2024